Fostamatinib is currently used to treat chronic adult idiopathic thrombocytopenic purpura (ITP), which has been poorly treated with previous therapy, by blocking platelet destruction and is the only approved SYK inhibitor on the market (66). This evidence concerns the gene SYK and autoimmune thrombocytopenic purpura.